<DOC>
	<DOCNO>NCT00354731</DOCNO>
	<brief_summary>We aim investigate ( 1 ) effect combine pentoxifylline corticosteroid , compare corticosteroid , patient primary nephrotic syndrome ; possible ( 2 ) effect pentoxifylline monotherapy patient primary nephrotic syndrome suitable intolerant standard corticosteroid therapy .</brief_summary>
	<brief_title>Efficacy Pentoxifylline Primary Nephrotic Syndrome</brief_title>
	<detailed_description>Pentoxifylline ( PTX ) phosphodiesterase inhibitor use clinically treat patient peripheral vascular disorder . In addition hemorheologic activity , PTX possess potent anti-inflammatory immunomodulatory property . In vivo , PTX show ability attenuate nephrotic syndrome secondary membranous glomerulonephritis lupus nephritis , reduce subnephrotic proteinuria early advance diabetic nephropathy . However , anti-proteinuric effect PTX traditionally attribute down-regulation tumor necrosis factor ( TNF ) -alpha . Whether inflammatory mediator also affect PTX never study . Our previous work show PTX inhibit cytokine albumin-induced monocyte chemoattractant protein ( MCP ) -1 production vitro , attenuate proteinuria association suppression renal MCP-1 messenger ribonucleic acid expression experimental glomerulonephritis . More recently , find PTX lower proteinuria modulate renal MCP-1 production subgroup human glomerular disease . In study , aim investigate whether combination PTX corticosteroid result additive reduction proteinuria , high remission rate patient primary nephrotic syndrome . The secondary objective study whether PTX monotherapy effective patient primary nephrotic syndrome suitable intolerant corticosteroid therapy . This study prospective , open-labeled , comparative study include primary nephrotic patient randomize 2 group . Group A receive oral PTX plus oral prednisolone , whereas group B receive oral prednisolone alone . The active treatment duration 1 year subgroup . The dose PTX 1,200 mg/day ( estimate glomerular filtration rate ( GFR ) ≧60 ml/min ) 800 mg/day ( estimate GFR 59-30 ml/min ) x 6 month , follow stepwise reduction ( 800 mg/day x 6 M , 400 mg/day x 6 M discontinue 18 M ) . The dose prednisolone 1 mg/kg/day initial 3 month , dose gradually taper , thus 6 month dose 0.5 mg/kg/day , 12 month dose reduce around 5-10 mg/day , discontinue 18 M. For patient consider suitable ( eg. , active chronic hepatitis B virus hepatitis C virus infection ) , intolerance ( eg. , concomitant diabetes mellitus , active peptic ulcer disease ) standard corticosteroid therapy , PTX 1,200 mg/day administer total 1 year . Serum urine specimen collect initiation therapy ( day 0 ) , month 1 , 3 , 6 , 12 commencement therapy . GFR calculate Cockcroft-Gault simplify Modification Diet Renal Disease ( MDRD ) formula . Urinary protein excretion quantitated spot urine protein/creatinine ratio . All biochemical immunological analysis perform Department Laboratory Medicine , National Taiwan University Hospital . Serum urine sample measure inflammatory mediator podocyte marker use commercial ELISA kit .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Nephrotic Syndrome</mesh_term>
	<mesh_term>Nephrosis</mesh_term>
	<mesh_term>Pentoxifylline</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<criteria>biopsiedproved primary glomerular disease , nephrotic syndrome History allergy pentoxifylline , Females nursing pregnant , Congestive heart failure ( New York Heart Association functional class III IV ) , Unstable angina , myocardial infarction , coronary artery bypass graft surgery , percutaneous coronary intervention , within past 6 month prior sign inform consent form , Cerebral hemorrhage within past 6 month prior sign inform consent form , Retinal hemorrhage within past 6 month prior sign inform consent form , Known suspect secondary hypertension , Uncontrolled hypertension systolic blood pressure &gt; 200 mmHg and/or diastolic blood pressure &gt; 110 mmHg , Liver cirrhosis , Biliary obstructive disorder , Active malignancy infection , Uncontrolled diabetes mellitus , GFR ≦ 30 ml/min/1.73 m2</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>nephrotic syndrome , pentoxifylline , corticosteroid</keyword>
</DOC>